SCI时时刷

search
+
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. H...
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Variants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients w...
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Though several anti-PD-1/PD-L1 antibodies approved for monotherapy in microsatellite instability-high or mismatch repair-d...
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. Ho...
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages
The long-term effectiveness of immunotherapies against Multiple Myeloma (MM) remains elusive, demonstrated by the inevitab...
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressing, life-threatening syndrome characterized by excessive im...
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation
Mitochondrial DNA (mtDNA) variants in patients with myelodysplastic neoplasms (MDS) are shown to be prognostic of outcomes...
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial
Early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a distinct subtype of T-ALL/LBL, characterized by ...
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation
Chimeric Antigen Receptor T (CAR-T) cell therapy has significantly advanced in treating B-cell acute lymphoblastic leukemi...
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment
Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R)...
Global cancer statistics for adolescents and young adults: population based study
Global cancer statistics for adolescents and young adults: population based study
Accurate and up-to-date estimates of the global cancer burden in adolescents and young adults (AYA) are scarce. This study...
Predictive value of tumor microenvironment on pathologic response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas
Predictive value of tumor microenvironment on pathologic response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas
Undifferentiated pleomorphic sarcomas (UPS) represent a prevalent and aggressive subtype of soft tissue sarcomas (STS) in ...
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis
Due to spatial and genomic independence, mitochondria possess a translational mechanism distinct from that of cytoplasmic ...
NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression
NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression
Tumor cells develop multiple mechanisms to facilitate their immune evasion. Identifying tumor-intrinsic factors that suppo...
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China
In recent years, cell therapy research and commercialization have significantly accelerated, especially after the US FDA a...
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation
Increased Epstein‒Barr virus reactivation following prophylaxis for cytomegalovirus infection after haploidentical haematopoietic stem cell transplantation
Letermovir (LTV) prophylaxis is effective in reducing the incidence of clinically significant cytomegalovirus (CMV) infect...
Consensus, debate, and prospective on pancreatic cancer treatments
Consensus, debate, and prospective on pancreatic cancer treatments
Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease, despite the improvement of multi...
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
The epigenetic factors KAT6A (MOZ/MYST3) and KMT2A (MLL/MLL1) interact in normal hematopoiesis to regulate progenitorsR...
Landscape of biallelic DNMT3A mutant myeloid neoplasms
Landscape of biallelic DNMT3A mutant myeloid neoplasms
DNA methyltransferase 3 A mutations (DNMT3AMT) are frequent in myeloid neoplasia (MN) and mostly heterozygous. Ho...
Targeting GPRC5D for multiple myeloma therapy
Targeting GPRC5D for multiple myeloma therapy
Given its nearly ubiquitous expression on plasma cells and limited expression on essential normal tissue, the G protein-co...
Correction: SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
Correction: SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. I...
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy i...
c-Myc alone is enough to reprogram fibroblasts into functional macrophages
c-Myc alone is enough to reprogram fibroblasts into functional macrophages
Macrophage-based cell therapy is promising in solid tumors, but the efficient acquisition of macrophages remains a challen...
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies
Heat shock proteins are essential molecular chaperones that play crucial roles in stabilizing protein structures, facilita...
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution
Metabolic reprogramming provides tumors with an energy source and biofuel to support their survival in the malignant micro...
METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma
METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma
Ferroptosis, characterized by iron-dependent lipid peroxidation, emerges as a promising avenue for hepatocellular carcinom...
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Blinatumomab has emerged as a promising component of first-line therapy for acute B-cell precursor lymphoblastic leukemia ...
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation
Targeted protein degradation of neosubstrates plays a crucial role in hematological cancer treatment involving immunomodul...
New strategies in soft tissue sarcoma treatment
New strategies in soft tissue sarcoma treatment
Soft tissue sarcomas (STS) have long been a formidable challenge in oncology, partly because of their rarity and diversity...
阅读更多
format_indent_increase